Skip to content

Study · Animal study (in vivo) · rat · 1989

1 result

Dimeric dermorphin peptides: central administration suppresses gastric acid secretion through interaction with mu-type opioid receptor.

Guglietta A, Irons BJ, Lazarus LH, de Castiglione R, Melchiorri P

Methods and findings in experimental and clinical pharmacology1 Nov 1989Cited by 2 (Europe PMC)

PMID2560103 (opens in a new tab)PepBankPUB-02560103
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In pylorusligated rats, centrally administered dermorphin significantly inhibited gastric acid output at 0.5 nmol.

    In plain wordsIn rats with pylorus ligation, central dermorphin administration significantly reduced gastric acid output.

    Peptide
    Dermorphin
    Outcome
    DecreaseGastric acid output
    Study

    ratn: not reported in source

    Pylorusligated rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.5 nmol · centralAs given in this study (rat).

    Source sentences

    Summary
    At a dose of 0.5 nmol dermorphin, and the dimeric analogs di-[D-Arg2,Sar4]-tetra-DM2, di-penta-DM0, di-[Sar4]-penta-DM0, di-[D-Arg2,Sar4]-penta-DM0, di-[D-Ala4]-penta-DM0 and di-DM0, and di-DM0, inhibited gastric acid output in a statistically significant manner (P less than 0.05).
    1 context sentence
    Summary · context
    The effect of centrally administered dermorphin and a series of dimeric dermorphin analogs on gastric acid secretion was studied in pylorusligated rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.